Sei Investments Co. Sells 33,727 Shares of BioNTech SE (NASDAQ:BNTX)

Sei Investments Co. lessened its stake in BioNTech SE (NASDAQ:BNTX) by 59.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 23,221 shares of the company’s stock after selling 33,727 shares during the quarter. Sei Investments Co.’s holdings in BioNTech were worth $2,648,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jones Financial Companies Lllp increased its holdings in BioNTech by 110.3% in the 4th quarter. Jones Financial Companies Lllp now owns 469 shares of the company’s stock worth $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. increased its stake in shares of BioNTech by 823.5% in the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company’s stock valued at $88,000 after buying an additional 700 shares during the period. GAMMA Investing LLC raised its holdings in BioNTech by 48.2% in the 4th quarter. GAMMA Investing LLC now owns 923 shares of the company’s stock valued at $105,000 after buying an additional 300 shares during the last quarter. Generali Investments CEE investicni spolecnost a.s. acquired a new stake in BioNTech during the 4th quarter worth approximately $137,000. Finally, AlphaCentric Advisors LLC acquired a new stake in BioNTech during the 4th quarter worth approximately $168,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

Analysts Set New Price Targets

BNTX has been the topic of a number of recent research reports. Canaccord Genuity Group reiterated a “buy” rating and set a $171.44 price target on shares of BioNTech in a report on Tuesday, March 11th. Citigroup initiated coverage on BioNTech in a research note on Thursday, March 13th. They issued a “buy” rating and a $145.00 price target for the company. Truist Financial started coverage on BioNTech in a research note on Friday, January 10th. They issued a “buy” rating and a $172.00 price objective on the stock. Wells Fargo & Company began coverage on shares of BioNTech in a research report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price for the company. Finally, HC Wainwright lowered their price target on shares of BioNTech from $150.00 to $145.00 and set a “buy” rating for the company in a report on Tuesday. Three equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $143.44.

BioNTech Price Performance

Shares of BNTX stock opened at $88.05 on Friday. The firm has a market capitalization of $21.13 billion, a price-to-earnings ratio of -41.93 and a beta of 1.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. The stock’s 50-day simple moving average is $108.81 and its 200-day simple moving average is $112.88. BioNTech SE has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.70. The company had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue for the quarter was down 19.5% compared to the same quarter last year. During the same period last year, the firm posted $1.90 EPS. As a group, equities analysts forecast that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.